Heron Therapeutics Initiated at Buy by Rodman & Renshaw
Heron Therapeutics Initiated at Buy by Rodman & Renshaw
Express News | Rodman & Renshaw Initiates Coverage On Heron Therapeutics With Buy Rating, Announces Price Target of $7
Heron Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/13/2024 89.19% Rodman & Renshaw → $7 Initiates Coverage On → Buy 05/16/2024 35.14% Needham $5 → $5 Reit
FDA Expands AstraZeneca's (AZN) Farxiga Label in Pediatric T2D
Rodman & Renshaw Initiates Heron Therapeutics(HRTX.US) With Buy Rating, Announces Target Price $7
Rodman & Renshaw analyst Elemer Piros initiates coverage on $Heron Therapeutics(HRTX.US)$ with a buy rating, and sets the target price at $7.According to TipRanks data, the analyst has a success rate
Connect Biopharma: Quart Was Most Recently CEO at Heron Therapeutics >CNTB
Connect Biopharma: Quart Was Most Recently CEO at Heron Therapeutics >CNTB
Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug
Amgen's (AMGN) Uplizna Meets Study Goal for Rare Disease
Northland Securities Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Maintains Target Price $9
Northland Securities analyst Carl Byrnes maintains $Heron Therapeutics(HRTX.US)$ with a buy rating, and maintains the target price at $9.According to TipRanks data, the analyst has a success rate of 3
Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody
Heron Therapeutics, Inc. (NASDAQ:HRTX) Surges 31% Yet Its Low P/S Is No Reason For Excitement
Heron Therapeutics, Inc. (NASDAQ:HRTX) shares have had a really impressive month, gaining 31% after a shaky period beforehand.
J&J's (JNJ) Oral Pill Improves Depression & Insomnia Symptoms
Merck (MRK) to Buy Private Ophthalmology Company EyeBio
Pleasing Signs As A Number Of Insiders Buy Heron Therapeutics Stock
Express News | Heron Therapeutics Announces Prior Approval Supplement Submission To FDA For ZYNRELEF VAN
Express News | Heron Anticipates FDA Action on Zynrelef Within 4-6 Months
Express News | Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for Zynrelef® Vial Access Needle ("Van")
Top 3 Health Care Stocks That May Crash In May
As of May 24, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.The RSI is a momentum indicator
Pfizer (PFE) Starts Another Cost-Cut Plan to Save $1.5B by 2027
What Makes Heron Therapeutics (HRTX) a Strong Momentum Stock: Buy Now?
No Data